Ben Stevens
Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.
Ben Stevens · page 13
- Cultivation
Business Brief: Canify and MG Health Announce Merger
German pharmaceutical cannabis company Canify AG and African medical cannabis cultivator MG Health Limited have announced a planned merger, marking yet another M&A deal in a market widely expected to see an incoming wave of consolidation.
- Industry Trends
Is the German Cannabis Boom Slowing Down, or Simply Normalising?
Germany’s cannabis imports, according to the latest figures from BfArM, nearly tripled in size in 2025, cementing it beyond any doubt as the engine behind Europe’s medical cannabis boom.
- Hemp Industry
House Agriculture Committee Advances Farm Bill With No Relief for Hemp Industry
The US House Agriculture Committee has voted to advance the 2026 farm bill without adopting any provisions to delay or repeal the incoming ban on intoxicating hemp.
- Retail & Brands
Canada’s Cannabis Retail Market Reaches C$5.5bn in 2024/25, But Growth Slowing
Canadian adult-use cannabis sales reached C$5.5 billion in the fiscal year ending 31 March 2025, a 6.1% increase on the prior year, according to new data from Statistics Canada, though the pace of growth continued to slow for the third consecutive year.
- Clinical Research
The Cannabis Mental Health Evidence Gap: Association vs. Causation
In our latest Beyond the Abstract, we dive into cannabis use and its impact on mental health, a controversial and understudied field, but one of vital importance for both patient safety and potential relief for millions.
- Medical Cannabis
Why Medical Cannabis Clinics Should Be Knocking on Union Doors
When a crew trainer at a fast food restaurant told her manager she had recently been prescribed medical cannabis, she came prepared.
- Clinical Research
Ananda Pharma Cleared to Begin Dosing in NHS-Backed CBD Endometriosis Trial
Ananda Pharma has cleared the final regulatory hurdle needed to begin its ENDOCAN Phase 2 clinical trial, receiving approval from the MHRA and NHS Health Research Authority to commence dosing of its proprietary MRX1 CBD oral solution in women with endometriosis-associated pain.
- Industry Trends
Germany’s Post-CanG Import Surge Loses Steam as Q4 Growth Stalls
Germany’s imports for 2025 surpassed 200 tonnes for the first time, exceeding the country’s already revised import quota for the second time in a year.
- Industry Trends
The Scramble for Europe
Last month, the German cannabis market saw its most significant consolidation deal to date, as Canadian heavyweight Organigram announced plans to acquire Sanity Group in a deal worth up to €250m.
- Clinical Research
‘You Can’t Treat What You Can’t Measure’ – The Plan to Make the Endocannabinoid System Impossible to Ignore
Across global cannabis markets, the average levels of THC content are continuing a sustained, exponential and well-documented rise.
- CBD Market
Clinical Evidence vs. Food Law: Europe’s CBD Dilemma
The CBD sector has had a turbulent few weeks on both sides of the Channel, with the European Food Safety Authority (EFSA) terminating four novel food applications, just days after announcing incredibly restrictive new safety limits.
- CBD Market
UK CBD: A Regulator Finding Its Stride, A Sector Holding Its Breath
The UK’s CBD novel foods programme enters 2026 with its autumn ministerial approval target still nominally intact, but facing increasing pressure on multiple fronts.
